In the present study we describe the effect of oral application of mAB specific for ETEC F4ac fimbriae in an experimental ETEC challenge model in neonatal germfree piglets. The results show that mAB, specific for different F4ac epitopes protect animals against ETEC specific pathology. Moreover, the results show that protection is independent of F4ac epitope specificity.
No takes yet. Share an insight, caveat, or question.
Geus et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: